

# PRECISE EXCISION OF HTLV-1 PROVIRUS WITH DESIGNER-RECOMBINASES

## Authors:-

Rojo Romanos T<sup>1</sup>, Millen S<sup>2</sup>, Beschorner N<sup>3</sup>, Karpinski J<sup>1</sup>, Paszkowski-Rogacz M<sup>1</sup>, Suerun D<sup>1</sup>, Lansing F<sup>1</sup>, Schneider PM<sup>1</sup>, Sonntag J<sup>1</sup>, Hauber J<sup>3</sup>, Thoma-Kress AK<sup>2</sup>, Buchholz F<sup>1</sup>

<sup>1</sup>TU Dresden, UCC, Medical Systems Biology, Medical Faculty, Dresden, Germany

<sup>2</sup>Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

<sup>3</sup>HPI - Leibniz Institute for Experimental Virology, Hamburg, Germany

## Background:

The oncogenic Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of the incurable disease adult T-cell leukemia/ lymphoma (ATL/ L), after decades of viral latency. In recent years, genome editing tools have emerged as promising antiviral agents. In this study, we engineered a Cre-derived site-specific recombinase to target HTLV-1 infected cells.

## Methods:

Substrate linked directed evolution, flow cytometry, Western blot, quantitative PCR (qPCR)

## Results:

To excise the HTLV-1 provirus, we identified a conserved *loxP*-like sequence (*hoxLTR*) present in the long terminal repeats (LTR) of the virus. Using substrate linked directed evolution, we isolated two designer-recombinases (E5 and G9), which efficiently recombine the *hoxLTR* sequence in bacteria. Furthermore, E5 and G9 show recombination activity in human cells (CD4<sup>+</sup> Jurkat T-cells, 293T), not only in the context of a fluorescent reporter or an HTLV-1 oncoprotein Tax expression vector, but also when challenged with the full proviral sequence. Moreover, in HTLV-1 chronically infected SP cells, expression of G9 led to the excision of proviral DNA from the host genome.

## Conclusion:

In summary, our data suggest that recombinase mediated excision of the HTLV-1 provirus represents a promising strategy to reverse HTLV-1 infections and bears potential for future clinical applications.

## Disclosure of Interest Statement:

Frank Buchholz and Joachim Hauber declare competing financial interests.

## Acknowledgement of Funding:

This study was funded by the Federal Ministry of Education and Research (BMBF) of the Federal Republic of Germany [01KI2023] and by the European Union [ERC 742133, H2020 UPGRADE 825825].